You are here

Articles

BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from expert panel on behalf of European LeukemiaNet

published: 17 March 2015

INTERIM Confirms 5-Year Efficacy of Intermittent Imatinib in CML

published: 22 January 2015

Ponatinib Shows Promise in CML Even After Early Trial Termination -

published: 22 January 2015

PTCH1 Expression Predicts Failure of Imatinib in Chronic Myeloid Leukemia

published: 9 January 2015

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

published: 7 January 2015

New substance overcomes treatment-resistance in leukemia

published: 5 January 2015

Tyrosine Kinase Inhibitors Are Linked to Platelet Dysfunction in Patients with Chronic Myeloid Leukemia

published: 5 January 2015

Abstracts and notes on CML presentations from ASH 2014 San Francisco

published: 15 December 2014

PF-114, a potent and selective inhibitor of native and mutated BCR/ABL is active against Philadelphia chromosome- positive (Ph+) leukemias harboring the T315I mutation

published: 9 December 2014

The BCL2 inhibitor ABT-199 significantly enhances imatinib-induced cell death in chronic myeloid leukemia progenitors

published: 9 December 2014

Chronic Anemia in CML Patients Responsive to Imatinib

published: 6 December 2014

European Medicines Agency Press Release: Ponatinib

published: 25 October 2014

Summary: European LeukemiaNet recommendations (2013) for the management of Chronic Myeloid Leukemia

published: 7 October 2014

Generics :EMA EPAR (European public assessment report) for Imatinib Teva

published: 6 October 2014

Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

published: 25 September 2014

Could sticky cells cause drug resistance in chronic blood cancer?

published: 14 September 2014

New Molecule Could Treat TKI-Resistant CML

published: 14 September 2014

Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia

published: 9 August 2014

Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond

published: 7 August 2014

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

published: 5 August 2014